ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo
About authors
1 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia
2 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
3 Lomonosov Moscow State University, Moscow, Russia
4 Sechenov University, Moscow, Russia
Correspondence should be addressed: Andrey E. Sinyavin
Gamalei, 16, Moscow, 123098, Russia; ur.xednay@39isyerdna
About paper
Funding: the study was supported by the Russian Ministry of Health, grant № 121111200070-4 (P16).
Acknowledgments: the authors would like to thank the staff of N.I. N.F. Gamaleya A. Zakharova and T. Remizov for organizing the supply of reagents for the study.
Author contribution: Sinyavin AE — design of the experiment, study of antiviral activity, data analysis, writing the text; Russu LI — work with the virus and animals; Vasina DV — work with animals; Shidlovskaya EV, Kuznetsova NA — PCR analysis, data processing; Gushchin VA — research supervision, text editing; Gunzburg AL — approval of the research concept.
Compliance with ethical standards: the study was approved by the ethics committee of the Federal State Budgetary Institution “N.N. N.F. Gamaleya" of the Ministry of Health of the Russian Federation (protocol № 27 of June 6, 2022); conducted in compliance with the principles of the Declaration of Helsinki of the World Medical Association.
Received: 2022-12-05
Accepted: 2022-12-20
Published online: 2022-12-31
|
No data available...